<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3301764</article-id><article-id pub-id-type="publisher-id">cc436</article-id><article-id pub-id-type="doi">10.1186/cc436</article-id><article-categories><subj-group subj-group-type="heading"><subject>Meeting Abstract</subject></subj-group></article-categories><title-group><article-title>Fluconazole prophylaxis of systemic candida infection in non-neutropenic critically ill patients: a prospective randomized study</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Parizkova</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Dostal</surname><given-names>P</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Cerny</surname><given-names>V</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Department of Anesthesiology and Intensive Care, Charles University, Faculty of Medicine, 500 05 Hradec Kralove, Czech Republic</aff><pub-date pub-type="ppub"><year>1999</year></pub-date><pub-date pub-type="epub"><day>16</day><month>3</month><year>2000</year></pub-date><volume>3</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">19th International Symposium on Intensive Care and Emergency Medicine</named-content></supplement><fpage>P061</fpage><lpage>P061</lpage><permissions><copyright-statement>Copyright &#x000a9;1999 Current Science Ltd</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Current Science Ltd</copyright-holder></permissions><self-uri xlink:href="http://ccforum.com/content/3/S1/P061"/><conference><conf-date>16-19 March 1999</conf-date><conf-name>19th International Symposium on Intensive Care and Emergency Medicine</conf-name><conf-loc>Brussels, Belgium</conf-loc></conference></article-meta></front><body><sec><title>Introduction</title><p>Systemic Candida infection has been associated with increased morbidity and mortality in patients requiring intensive care. Fluconazole (F) is the preferred therapy in <italic>Candida albicans</italic> infection. The aim of the study was to evaluate effect of daily prophylactic fluconazole administration on the incidence of systemic Candida infection.</p></sec><sec sec-type="methods"><title>Methods</title><p>After institutional approval 38 critically ill patients were prospectively studied. In 18 patients (group F) presumptive fluconazole therapy after admission was started in daily dose 100 mg intravenously until discharge or evidence of systemic candida infection, which was treated using standard dosage. Control group (C) consisted of 20 patients. Apache II, candida colonization, selected risk factors for candidemia (central venous and urinary catheters, parenteral nutrition, corticosteroids therapy, broad-spectrum antibiotics, H<sub>2</sub>-receptor antagonists), length of ICU and hospital stay, ventilatory days, incidence of candida albicans and non albicans candida species were recorded. The cultures from nasopharynx, trachea, urine, stool and blood stream were taken. Values are expressed as a mean (SD), <italic>t</italic>-test, Mann Whitney Rank Sum test, z-test were used for statistical analysis, <italic>P</italic> &#x0003c; 0.05 was considered significant.</p></sec><sec><title>Results</title><p>Selected results are presented in the Table.</p></sec><sec><title>Conclusion</title><p>There were no significant differences in incidence of candida colonization and proportion of albicans v. non albicans species between both groups. Hospital and ICU stay and length of ventilatory support were nonsignificantly longer in group F. Clinical usefulness of early fluconazole prophylaxis needs to be further evaluated.</p><table-wrap id="T1" position="float"><label>Table</label><table frame="hsides" rules="groups"><thead><tr><th/><th align="center">Group F</th><th align="center">Group C</th></tr></thead><tbody><tr><td align="left">APACHE II</td><td align="center">23.6 (3.8)</td><td align="center">22.6 (4.7)</td></tr><tr><td align="left">ICU stay (days)</td><td align="center">17.6 (8.9)</td><td align="center">11.5 (4.1)</td></tr><tr><td align="left">Hospital stay (days)</td><td align="center">21 (9)</td><td align="center">15.7 (6.2)</td></tr><tr><td align="left">Ventilatory days</td><td align="center">17.6 (11.9)</td><td align="center">11.9 (4.9)</td></tr><tr><td align="left"><italic>Candida</italic> colonization</td><td align="center">27%</td><td align="center">33%</td></tr><tr><td align="left"><italic>Candida albicans</italic></td><td align="center">10 (66%)</td><td align="center">13 (81%)</td></tr><tr><td align="left">Non <italic>albicans</italic> species</td><td align="center">5 (33%)</td><td align="center">3 (19%)</td></tr></tbody></table></table-wrap></sec></body></article>